JONATHAN C. JAVITT, M.D., M.P.H.
Chief Executive Officer
Dr. Javitt has played leadership roles in seven successful healthcare IT and biopharma startups with public exits. He has additionally led drug-development engagements for Merck, Allergan, Pharmacia, Novartis, and Pfizer. He was appointed to healthcare leadership roles under Presidents Reagan, George H.W. Bush, Clinton, and George W. Bush. In the latter role he was commissioned to lead the White House policy for universal adoption of Health IT and establishment of the Office of the National Coordinator. He is a graduate of Princeton University, Cornell University Medical College, Harvard School of Public Health, the Wills Eye Hospital, and Johns Hopkins Medical School. Dr. Javitt has published more than 200 scientific works in the areas of health outcomes and pharmacoeconomics that have been cited by more than 16,000 people.
PHILIP T. LAVIN, PH.D.
Dr. Lavin is a highly-respected biostatistician with more than 30 years of experience supporting the design and analysis of clinical trials. Previously, he was a member of the biostatistics faculty at the Harvard School of Public Health and a member of the Department of Surgery at Harvard Medical School where he was affiliated for over 25 years. He co-founded Boston Biostatistics in 1983, a company now known as Aptiv Solutions. During his career, Dr. Lavin has served as lead biostatistician for 50 FDA approvals, including 38 PMAs, more to date than any other biostatistician. He has also served as a Special Government Employee for 30 years where he has advised FDA on complex statistical and policy issues.
ROBERT BESTHOF, M.I.M.
Chief Commercial & Patient Officer
Mr. Besthof is a global biopharmaceutical executive with a 25+year career covering global pipeline & country operational marketing & sales roles. He has managed numerous specialty diseases areas, including small as well as billion dollar brands in Ophthalmology, Neuroscience, Pain, Pulmonary Vascular Disease, etc. His teams have played key roles in translating new science into investable commercial paths, reshaping markets, launching breakthrough products, and closing numerous licensing deals. Mr. Besthof has worked for Eli Lilly, Wyeth, and most recently Pfizer, as Vice President Commercial Development Neuroscience & Pain. Earlier in his career he worked for Deutsche Bank and for various consulting firms. He holds a B.A. from Case Western Reserve University and a Masters in Int’l Management from the Thunderbird School of Global Management.
RICHARD C. SIEGEL, PH.D.
Chief Scientific Officer & EVP of Drug Development and Manufacture
Dr. Siegel brings extensive expertise in both technical and strategic aspects of early and late stage drug development. His experience includes process development and manufacture of small molecule drugs, monoclonal antibodies, therapeutic proteins and conjugates, peptides, cellular products and oligonucleotides. During his career, Dr. Siegel has held a number of high-level drug development and manufacturer positions within the Johnson & Johnson family of companies. These include Vice President of R&D and Global Head of Portfolio Management at Janssen Research and Development.
Brian J. Del Buono, Ph.D., J.D.
Chief Legal Officer
Brian has over 30 years of multinational scientific and legal experience in FDA-regulated pharmaceuticals and biologics, with an emphasis on both branded and generic FDA-regulated products, intellectual property, regulatory affairs, strategic business development, mergers and acquisitions, corporate governance and corporate transactions including licensing. He also has substantial experience in biotech/pharma R&D innovation and management, and has had key responsibilities in large merger integration efforts. Prior to joining NeuroRx, Brian was VP/Chief Legal & Regulatory Officer for Stuart Therapeutics, Sr. VP/Chief Legal Officer & Corporate Secretary for The Sun Products Corporation, and was a partner at Sterne, Kessler, Goldstein & Fox, PLLC. Before entering into his legal practice, Brian spent nearly 10 years in academic and corporate biopharma R&D, most recently with Becton Dickinson & Co. Brian holds a J.D., cum laude, from Georgetown University Law Center, an M.S. and a Ph.D. in Microbiology/Biochemistry from The Pennsylvania State University, and was a postdoctoral fellow in Biochemistry and Hematology/Oncology at Boston University School of Medicine.
James H. Brandon, C.P.A.
Comptroller & Acting CFO
James H. Brandon, CPA, has practiced as a Maryland licensed Certified Public Accountant for over 35 years. Mr. Brandon has been a partner in several firms, sold a practice to American Express, was the managing member of a Caribbean island resort, and is currently a sole practitioner serving the Washington DC. Metropolitan area. His clients span the country and he currently has business and individual clients in over 25 states.
Mr. Brandon's area of concentration is business and individual accounting and taxation. Mr. Brandon is well versed in accounting systems and has conducted seminars in the use of certain software. Mr. Brandon was the auditor of several local governments in Maryland. Mr. Brandon also prepares probate court accounting for personal representatives. Mr. Brandon is also a court-appointed bankruptcy CPA.
Mr. Brandon is a member of
DENNIS K. MCBRIDE, Ph.D.
Chief Strategy Officer & Senior Scientist
Dr. McBride has led numerous national and international initiatives in neuroscience and its interface with information technology, national security, and medical technology/drug development within the federal government, three of which are now multi-billion dollar enterprises. He began his career as a medical scientist in Naval Aviation and ergonomics and served in eight nationally-prominent laboratories and headquarters organizations, including the Defense Advanced Research Projects Agency (DARPA), Naval Aerospace Medical Research Lab, Naval Research Lab, the Office of Naval Research, and the Naval Medical Research Institute. Upon retiring as a highly decorated senior officer (O-6), he assumed the leadership of the Potomac Institute for Policy Studies, which he continues to serve as President Emeritus. Following his ten year term, he was recruited back to the National Defense University to lead the Center for Technology and National Security Policy, culminating his government career there as Senior Executive-4 (Civilian equivalent to Rear Admiral/Vice Admiral).
Dennis has served as adviser to Cabinet Secretaries, congressional committees, and to major corporate C-Suite executives. His educational background includes formal enrollment at the University of Georgia, Naval Aerospace Medical Institute (Flight Surgeon School), the University of Southern California, the London School of Economics, and Harvard Business School, with award of the Ph.D. in experimental psychology, four master’s degrees, and additional postdoctoral education in aviation medicine, systems engineering science, and strategic disruption. He has published widely, was elected by faculty in 1999 to full professor, and has served at multiple universities, full- and part-time in colleges of Arts & Sciences, Engineering, Public Policy, and Medicine. For the past 12 years, Dr. McBride has served as adjunct Professor at Georgetown University School of Medicine and co-Director of Georgetown’s Regulatory Science Program.
ROBERT RISINGER, M.D.
Vice President of Clinical Development
Dr Risinger trained in psychiatry at Emory University completing psychopharmacology and imaging fellowships at NIMH. He then served in the US Air Force becoming Director of Inpatient Psychiatry at Wilford Hall in San Antonio.
He has over 20 years of clinical and academic experience in directing tertiary refractory mood disorders clinics using psychotherapeutic, pharmacologic, ECT and implantable medical devices to address PTSD, Bipolar disorder, substance abuse and other neuropsychiatric conditions.
Interested in serving a greater clinical population through pharmaceutical development, he was medical director at Janssen, Bristol-Myers Squibb, and Alkermes. He has lead successful Ph 1-4 development from First-In-Human through NDA/sNDA approvals of compounds for psychosis, depression, anxiety, chronic pain and Alzheimer’s.